Clinical Experience on the Use of a Single-day, Two-injection Start Initiation Regimen of Aripiprazole Once Monthly in Patients With Schizophrenia in Spain: SaTISfy Study.
Journal
Journal of psychiatric practice
ISSN: 1538-1145
Titre abrégé: J Psychiatr Pract
Pays: United States
ID NLM: 100901141
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
medline:
25
3
2024
pubmed:
25
3
2024
entrez:
25
3
2024
Statut:
epublish
Résumé
The two-injection start (TIS) initiation regimen was recently approved for aripiprazole once monthly 400 mg (AOM400), with potential benefits in adherence. The SaTISfy study described in this article analyzed Spanish psychiatrists' perspectives on hospitalization lengths of stay, schizophrenia management, and the use of AOM400-TIS. The authors describe an ecological study of aggregated data collected using a 41-question survey. Fifty psychiatrists were asked to provide their perceptions of their patients with schizophrenia and treatment with AOM400. The psychiatrists reported that lack of treatment adherence was the main reason for hospitalization for 58.3% of their patients diagnosed with schizophrenia. Aripiprazole, in any formulation, was the most commonly prescribed therapeutic option, being prescribed for a mean (SD) of 2.5 (0.9) out of 5 patients, while 98% of psychiatrists chose AOM400-TIS for patients who failed to adhere to previous treatments. Patients with schizophrenia, regardless of their treatment, were hospitalized for an average of 17.7 (3.93) days versus patients with schizophrenia treated with AOM400-TIS, who were hospitalized for an average of 14.2 (4.18) days, a reduction of 3.5 (3.86) days. Patients treated with AOM400-TIS showed a reduction of 5 (4.18) days compared with the mean national duration of hospitalization for acute patients in psychiatry units in Spain (19.18 d). The surveyed psychiatrists reported that AOM400-TIS improved safety and tolerability. Most of the psychiatrists were satisfied with the administration and results of AOM400-TIS. Most of the psychiatrists (90%) also reported that fewer health care resources were consumed with AOM400-TIS, mainly due to a reduction in hospitalization days and in the use of concomitant medications. AOM400-TIS was considered to have a positive impact on the duration of hospitalization and thus on the use of health care resources. There was a positive perception of adherence, safety, and tolerability with the use of AOM400-TIS in patients with schizophrenia.
Identifiants
pubmed: 38526396
doi: 10.1097/PRA.0000000000000776
pii: 00131746-202403000-00002
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
82-94Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76.
World Health Organization (WHO). Schizophrenia: key facts. WHO Fact Sheet; January 10, 2022. Accessed March 1, 2024 https://www.who.int/news-room/fact-sheets/detail/schizophrenia.
National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults. NICE Clinical Guideline; February 12, 2014, updated November 2023. Accessed March 1, 2024 https://www.nice.org.uk/guidance/cg178/resources/psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-35109758952133.
Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008;8:32.
Abdel-Baki A, Medrano S, Maranda C, et al. Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis. Int Clin Psychopharmacol. 2020;35:221–228.
Stevens GL, Dawson G, Zummo J. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. Early Interv Psychiatry. 2016;10:365–377.
Lin D, Thompson-Leduc P, Ghelerter I, et al. Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis. CNS Drugs. 2021;35:469–481.
Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14:2–44.
Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400–1411.
Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015;11:2635–2647.
Kane JM, Schooler NR, Marcy P, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77:1217–1224.
Karlović D, Silić A, Crnković D, et al. Effects of aripiprazole long-acting injectable antipsychotic on hospitalization in recent-onset schizophrenia. Hum Psychopharmacol. 2021;36:e2763.
Peitl V, Štefanović M, Orlović I, et al. Long acting aripiprazole influences cognitive functions in recent onset schizophrenia. Psychopharmacology (Berl). 2021;238:1563–1573.
Preda A, Shapiro BB. A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert Opin Drug Saf. 2020;19:1529–1538.
European Medicines Agency (EMA). Abilify Maintena: Product Information. European Union, EMA; 2023. Accessed March 1, 2024 https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena.
Wang Y, Wang X, Harlin M, et al. An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection. Curr Med Res Opin. 2021;37:1961–1972.
Ministerio de Sanidad. Sistema de Información Sanitaria. Portal estadístico. Actividad en Hospitalización; 2022. Accessed March 1, 2024 https://pestadistico.inteligenciadegestion.sanidad.gob.es/publicoSNS/C/siae/siae/hospitales/actividad-asistencial/actividad-en-hospitalizacion.
Perez-Sola V, Roca M, Alonso J, et al. Economic impact of treatment-resistant depression: a retrospective observational study. J Affect Disord. 2021;295:578–586.
Halfdanarson O, Zoega H, Aagaard L, et al. International trends in antipsychotic use: a study in 16 countries, 2005-2014. Eur Neuropsychopharmacol. 2017;27:1064–1076.
Martin A, Bessonova L, Hughes R, et al. Systematic review of real-world treatment patterns of oral antipsychotics and associated economic burden in patients with schizophrenia in the United States. Adv Ther. 2022;39:3933–3956.
Jauhar S, Guloksuz S, Andlauer O, et al. Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence? BMC Psychiatry. 2012;12:27.
Bioque M, Mezquida G, Amoretti S, et al. Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia. Schizophr Res. 2022;243:32–42.
Kim B, Lee SH, Yang YK, et al. Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons. Schizophr Res Treatment. 2012;2012:560836.
Reymann S, Schoretsanitis G, Egger ST, et al. Use of long-acting injectable antipsychotics in inpatients with schizophrenia spectrum disorder in an academic psychiatric hospital in Switzerland. J Pers Med. 2022;12:441.
Arango C, Baeza I, Bernardo M, et al. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. Rev Psiquiatr Salud Ment (Engl Ed). 2019;12:92–105.
Fu AZ, Pesa JA, Lakey S, et al. Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia. BMC Psychiatry. 2022;22:250.
Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014;205:135–144.
Olivares JM, Fagiolini A. Long-term real-world effectiveness of aripiprazole once-monthly. Treatment persistence and its correlates in the Italian and Spanish clinical practice: a pooled analysis. Front Psychiatry. 2022;13:877867.
Olivares JM, Gonzalez-Pinto A, Paramo M, et al. Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study. Eur Psychiatry. 2021;64:e40.
Fagiolini A, Aguglia E, Ballerini A, et al. Real-world effectiveness of long acting aripiprazole: treatment persistence and its correlates in the Italian clinical practice. Psychiatry Res. 2019;272:698–706.
Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75:1254–1260.
Giordano G, Tomassini L, Cuomo I, et al. Aripiprazole long-acting injection during first episode schizophrenia—an exploratory analysis. Front Psychiatry. 2019;10:935.
Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73:617–624.
Fleischhacker WW, Sanchez R, Johnson B, et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol. 2013;28:171–176.
Schottle D, Janetzky W, Luedecke D, et al. Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. BMC Psychiatry. 2018;18:365.
Salvi V, Appignanesi C, Marpepa B, et al. Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia. Neuropsychopharmacol Rep. 2022;42:241–244.